Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley takes Proactive’s Stephen Gunnion through recent announcements that highlight significant progress in the company’s targeted drug delivery solutions. Tolley explained that Aptamer’s focus on precision medicine aims to tackle the challenges of systemic drug administration, offering targeted solutions to improve patient care and reduce side effects.
In its latest deal, a genetic medicines customer has selected to progress to the final commercial development phase for Aptemer’s Optimer delivery vehicles.
The company’s collaboration with the US biopharmaceutical partner showcased Optimer’s capability for specific cell-type targeting, validated through successful in-house and external testing. This achievement supports Aptamer’s pipeline, including an associated siRNA liver fibrosis project and partnership with AstraZeneca, and emphasises the potential for faster clinical development.
“The value will come through access to the intellectual property,” Tolley noted, describing how the company’s strategy pivots on commercial milestones and licensing agreements. Looking forward, Tolley shared optimism for more …